[1]
Lim W. Antiphospholipid antibody syndrome. Hematology Am Soc 2013; 1: 675-80.
[2]
Uziel YLR, Blaser S, Andrew M, Schneider R, Silverman ED. Cerebral vein thrombosis in childhood systemic lupus erythematosus. J Pediatr 1995; 126(5): 722-7.
[3]
Ravelli AMA. Antiphospholipid syndrome. Pediatr Clin North Am 2005; 52(2): 469-91.
[4]
Cervera RPJ-C, Font J, Khamashta MA, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46(4): 1019-27.
[5]
Arnson Y, Shoenfeld Y, Alon E, Amital H. editors. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010; 40(2): 97-108.
[6]
Erkan D, Yazici Y, Peterson M, Sammaritano L, Lockshin M. A cross sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002; 41(8): 924-9.
[7]
Kent M1 AF. Vogt E, Fyffe R, Ng AK, Rote N. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J Rheumatol 1997; 24(9): 1725-33.
[8]
Chapman J1 C-AM. Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8(2): 127-33.
[9]
Brey RLAR, Curb JD, Sharp DS, et al. β2-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction the honolulu heart program. Stroke Am Heart Assoc 2001; 32(8): 1701-6.
[10]
Mackworth-young CG. Antiphospholipid syndrome: Multiple mechanisms. Clin Exp Immunol 2004; 136(3): 393-401.
[11]
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46(4): 1019-27.
[12]
Eriksson K, Peltola J, Keränen T, Haapala A, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: A controlled study of 50 cases. Epilepsy research 2001; 46(2): 129-37.
[13]
Agrawal BL, Foa RP. Collagen vascular disease appearing as chorea gravidarum. Arch Neurol 1982; 39(3): 192-3.
[14]
Kittner S, Joseph C, Havstad S, et al. Anticardiolipin antibodies are an independent risk factor for 1st ischemic stroke. Neurology 1993; 43(10): 2069-73.
[15]
Miesbach W, Gilzinger A, Gökpinar B, Claus D, Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosurg 2006; 108(2): 135-42.
[16]
Tanne D, Hassin-Baer S. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep 2001; 3(4): 286-92.
[17]
Harris E, Gharavi A, Asherson R, Boey M, Hughes G. Cerebral infarction in systemic lupus: Association with anticardiolipin antibodies. Clin Exp Rheumatol 1983; 2(1): 47-51.
[18]
Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005; 64(10): 1490-3.
[19]
Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103(1): 33-7.
[20]
Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37(4): 568-71.
[21]
Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn A. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8(2): 127-33.
[22]
Wiechens B, Schröder JO, Pötzsch B, Rochels R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol 1997; 123(6): 848-50.
[23]
Deschiens M-A, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996; 27(10): 1724-30.
[24]
Sanna G, Bertolaccini M, Cuadrado M, Khamashta M, Hughes G. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003; 42(2): 200-13.
[25]
Brey RL. Differential diagnosis of central nervous system manifestations of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15(2): 133-8.
